ArticleHead and neck pathology2018
Neuroendocrine Carcinomas of the Larynx and Head and Neck: Challenges in Classification and Grading.
Article in Head and neck pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oral and Maxillofacial Neuroendocrine Carcinoma: A Systematic Review.Head and neck pathology · 2022Pooled it
- Historical Evolution of Terminology and Current Classification of Neuroendocrine Neoplasms of the Larynx and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Pathological subtype dictates survival and failure pattern in laryngeal neuroendocrine neoplasms: a 15-year single-institution experience.World journal of surgical oncology · 2026Article
- Article
- Neuroendocrine carcinomas of the larynx: a review of current literature and case analysis.Journal of surgical case reports · 2025Article
- Basic science and translational implications of current knowledge on neuroendocrine tumors.The Journal of clinical investigation · 2025Review
- The Expression of Neuroendocrine Markers in a Small Subset of Ameloblastoma with Implications of Clusterin.Cells · 2025Article
- Oropharyngeal Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN): A Case Report and Literature Review.Head and neck pathology · 2024Review
- Long-term outcomes and prognosis of neuroendocrine neoplasms of the head and neck: a cohort from a single institution.Journal of cancer research and clinical oncology · 2024Article
- Poorly differentiated neuroendocrine carcinoma originating in the subglottic larynx: A case report with imm unohistochemical study.Clinical case reports · 2024Article
- Article
- Calcitonin-secreting neuroendocrine tumor of the larynx, a diagnostic challenge of a rare neoplasm: a case report and literature review.AME case reports · 2024Article
- Top 10 Nested Pattern Head and Neck Lesions to Notice.Head and neck pathology · 2023Review
- Review
- Histomorphologic Spectrum of Laryngeal Neuroendocrine Carcinoma: A Rare Case.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Surgical palliation in poorly differentiated neuroendocrine carcinoma of the hypopharynx: Case report.Cancer reports (Hoboken, N.J.) · 2022Article
- Article
- Combined large cell neuroendocrine carcinoma and squamous cell carcinoma of the oropharynx: A collision course of tumors.Clinical case reports · 2022Article
- Oropharyngeal Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN): A Case Report and Literature Review.Head and neck pathology · 2021Review
- Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary neuroendocrine carcinomas (NECs) of the larynx and head and neck are an uncommon and heterogeneous group of neoplasms categorized by the 2017 WHO Classification of Head and Neck Tumors as: (a) well-differentiated (WD-NEC), (b) moderately-differentiated (MD-NEC), and (c) poorly-differentiated (PD-NEC) with small cell and large cell types. The classification incorporates elements of differentiation and grading and closely correlates to the 5-year disease specific survival of 100, 52.8, 19.3 and 15.3% for each diagnostic category. These survival rates are based on historical data limited by the previous lack of standard pathologic diagnostic criteria. The classification has de-emphasized the use of the terms "carcinoid" and "atypical carcinoid" as diagnostic categories. The adoption of uniform pathologic criteria for the classification of NECs of the head and neck should enable the design of high quality studies in order to understand the molecular alterations of these neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.